

Please amend the specification in adherence with 37 C.F.R. § 1.821-1.825 as follows:

IN THE SPECIFICATION:

Please replace the paragraph beginning on page 5, line 12, with the following amended paragraph:

Fig. 3 Comparison of the heavy chain variable region amino acid sequence of humanized immunoglobulin HuZAF(SEQ ID NO:10) and humanized immunoglobulins haf25(SEQ ID NO:11), and HuXAF(SEQ ID NO:9).

Please replace the paragraph beginning on page 11, line 3, with the following amended paragraph:

Position H11 does not fulfill the criteria for substitution given above, but nevertheless makes a significant contribution to neutralizing activity in humanized immunoglobulins incorporating this substitution. The desirability of substituting at this position was determined by substitution of various positions in a chimeric AF2 antibody (i.e., having mouse variable domains and human constant regions) with amino acids from equivalent positions in the human EU antibody (SEQ ID NOS:12 and 13). Substitution of position H11 caused a significant reduction in the neutralizing activity of the chimeric antibody for γ -IFN.

Please insert the accompanying paper copy of the sequence listing, page numbers 1-9, at the end of the application.

REMARKS

Applicants request entry of this amendment in adherence with 37 C.F.R. §§ 1.821-1.825. The information contained in the computer readable disk of Application No. 09/450,520 was prepared through use of the software program "PatentIn" and is identical to that of the paper copy. This amendment contains no new matter.

Attached hereto is a marked-up version of the changes made to the specification by the amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Vasquez et al.
Application No.:
Page 3

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (650) 326-2400
Fax: (650) 326-2422
JOL:adm
PA 3183346 v1

099224-11304
TOWNSEND and CREW LLP

[illegible]

Fig. 3 Comparison of the heavy chain variable region amino acid sequence of [mouse AF2,] humanized immunoglobulin HuZAF(SEQ ID NO:10) and humanized immunoglobulins haf25(SEQ ID NO:11), and HuXAF(SEQ ID NO:9).

Position H11 does not fulfill the criteria for substitution given above, but nevertheless makes a significant contribution to neutralizing activity in humanized immunoglobulins incorporating this substitution. The desirability of substituting at this position was determined by substitution of various positions in a chimeric AF2 antibody (i.e., having mouse variable domains and human constant regions) with amino acids from equivalent positions in the human EU antibody (SEQ ID NOS:12 and 13). Substitution of position H11 caused a significant reduction in the neutralizing activity of the chimeric antibody for γ -IFN.